Mirtazapina Tecnigen (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Tecnogen, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is prescribed for the management of major depressive disorder in adult patients, helping to improve mood, sleep and appetite.

GNH USA supplies Mirtazapina Tecnogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from consistent product availability and regulatory support across multiple markets.

Mirtazapine is used within the antidepressant drug class to treat depressive disorders. - Major depressive disorder: reduces depressive symptoms and improves overall mood and functioning. - Depressive episodes with insomnia: promotes sleep onset and improves sleep quality. - Depression with loss of appetite: may increase appetite and support weight gain in affected patients.

Mirtazapine may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome) - Suicidal thoughts or behavior, especially early in treatment - Hepatic dysfunction or jaundice - Seizures - Cardiovascular arrhythmias

When prescribing mirtazapine, clinicians should consider several safety aspects. - Assess hepatic function: adjust use in severe liver impairment. - Monitor weight: patients often experience weight gain. - Caution in elderly: increased risk of sedation and falls. - Avoid abrupt discontinuation: taper to reduce withdrawal symptoms. - Monitor for suicidal ideation: especially during the initial treatment period. - Store at ambient temperature: keep in the original pack, protect from moisture.

Mirtazapine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): potential serotonin syndrome. - CNS depressants (e.g., benzodiazepines, alcohol): enhanced sedation. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increased mirtazapine levels. - Alcohol: additive sedative effect.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce efficacy. - Antihypertensive drugs: additive blood‑pressure lowering. - Anticholinergic agents: may worsen dry mouth and constipation. - Other antidepressants (non‑serotonergic): monitor for additive side effects. - Warfarin: monitor INR for possible alteration.